These studies establish that blockade of MEK1 with small-molecule inhibitors can circumvent the protective effects of IGF-1 and increase the cytotoxic, proapoptotic action of 4-OHT and/or MIF on ER+ breast cancer cells with low and high levels of IGF-1R. The gene discussed is MAP2K1; the disease is breast carcinoma.